Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in Chronic Cluster Headache
NCT02964338Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2017
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in Cluster Headache (CH) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean Change From Baseline in the Overall Monthly Average Number of CH Attacks Up to Week 12. Started Jan 2017; status: terminated.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT02964338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964338.